Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma (MM) is a hematologic malignancy with limited treatment options for relapsed/refractory cases.
• Standard-of-care therapies are continuously evolving to improve patient outcomes.

Purpose of the Study:

• To evaluate the real-world safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma.
• To assess response rates, progression-free survival, and adverse events associated with teclistamab treatment.

Main Methods:

• A multi-institutional retrospective cohort study including 110 patients who received at least one dose of teclistamab.
• Analysis of overall response rate (ORR), very good partial remission (VGPR) rate, progression-free survival (PFS), and incidence of cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), and infections.

Main Results:

• An overall response rate (ORR) of 62% and a ≥ very good partial remission (VGPR) rate of 51% were observed.
• The 6-month progression-free survival (PFS) was 52%.
• Incidence of CRS was 56% and ICANS was 11%; infections occurred in 40% of patients, with grade ≥3 infections in 26%.

Conclusions:

• Teclistamab demonstrates significant efficacy in a heavily pre-treated relapsed/refractory multiple myeloma population.
• Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a substantially lower risk of infections.
• Real-world data supports teclistamab as a viable treatment option, with careful monitoring for CRS, ICANS, and infections being crucial.